After the COVID boom, mergers and acquisitions (M&A) in pharma and life sciences saw a decline as the industry corrected itself. Last year, M&A started to make a comeback. Arthur Wong, managing director, healthcare, at S&P Global Ratings, spoke with Pharmaceutical Executive and provided an in-depth analysis of how the trend is continuing and adapting in the new year.
Read the full article: Will the Return of Pharma Mergers and Acquisitions Continue? Q&A with Arthur Wong, Managing Director, Healthcare, S&P Global Ratings //
Source: https://www.pharmexec.com/view/arthur-wong-arthur-managing-director-healthcare-s-p-global-ratings